Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease in which scar tissue gradually builds up in the lungs, making it harder and harder to breathe. The median survival after diagnosis is 3 to 5 years, and there is currently no cure. Globally, about 18 out of every 100,000 people have IPF, making it relatively rare but serious enough to be a leading reason for lung transplants.
What Happens Inside the Lungs
Your lungs contain millions of tiny air sacs called alveoli, where oxygen passes into your bloodstream. In IPF, the cells lining these air sacs become damaged, and the body’s normal repair process goes haywire. Instead of healing properly, the lungs overproduce repair cells called fibroblasts. These fibroblasts deposit thick, stiff tissue (collagen and other structural proteins) where soft, flexible lung tissue should be.
Over time, this scarring destroys the architecture of the lung. The air sacs stiffen and thicken, so oxygen can no longer pass through efficiently. The scarring is progressive and irreversible, meaning the lung tissue that’s already been replaced by scar tissue won’t return to normal. The word “idiopathic” means the cause is unknown, which distinguishes IPF from other forms of pulmonary fibrosis that have a clear trigger like asbestos or radiation exposure.
Early Symptoms and How They Progress
IPF typically starts subtly. The two hallmark symptoms are shortness of breath that worsens over time and a persistent dry cough. Early on, you might only notice breathlessness during exercise, climbing stairs, or walking uphill. It’s easy to dismiss this as being out of shape or aging. Over months or years, the breathlessness creeps into everyday activities and eventually can occur at rest.
Other signs that often develop include fatigue, unexplained weight loss, and a condition called clubbing, where the fingertips widen and round out. When a doctor listens to the lungs with a stethoscope, they may hear a distinctive crackling sound often compared to the tearing of Velcro. Because these symptoms overlap with many other conditions, IPF is frequently misdiagnosed as asthma, heart failure, or COPD before the correct diagnosis is made.
Risk Factors and Genetics
While the exact cause of IPF remains unknown, several factors increase risk. Most people diagnosed are over 60, and men are affected more often than women. Cigarette smoking is one of the strongest environmental risk factors. Exposure to certain dusts and pollutants, including metal dust, wood dust, and air pollution, also appears to play a role.
Genetics matter significantly. A landmark study published in the New England Journal of Medicine identified a common genetic variant in a gene called MUC5B that is strongly linked to both familial and sporadic IPF. People carrying this variant produce roughly 37 times more of a specific mucus protein in their lungs than people without it. The leading theory is that this excess mucus impairs the lungs’ natural defenses against inhaled particles, causing ongoing low-level injury that, over decades, tips into fibrosis. Other genetic mutations involving proteins that maintain the lung lining and enzymes that protect chromosome stability have also been linked to IPF, suggesting the disease has multiple genetic pathways.
How IPF Is Diagnosed
Diagnosis relies heavily on a specialized type of CT scan called high-resolution computed tomography (HRCT). Radiologists look for a specific scarring pattern known as usual interstitial pneumonia, or UIP. The hallmarks of this pattern include honeycomb-like cysts and scarring concentrated in the lower portions and outer edges of the lungs. Updated guidelines from 2018 classify scan results into four categories: definite UIP, probable UIP, indeterminate, or an alternative diagnosis entirely.
When the scan shows a clear UIP pattern and there’s no identifiable cause for the scarring (no history of drug toxicity, autoimmune disease, or significant occupational exposure), a diagnosis of IPF can be made without a lung biopsy. In less clear-cut cases, distinguishing IPF from conditions like chronic hypersensitivity pneumonitis (an immune reaction to inhaled substances) can be challenging. CT findings sometimes overlap, and a surgical lung biopsy remains the gold standard when imaging alone isn’t definitive.
Treatment Options
Two medications are approved worldwide specifically for IPF. Both are antifibrotic drugs, meaning they work by slowing down the scarring process rather than reversing it. In real-world studies tracking patients over five years, both medications reduced the rate of lung function decline by a similar amount, with no significant difference in survival between them. Patients on either drug lost roughly 660 to 700 milliliters of lung capacity over five years, which is slower than the decline seen without treatment.
Side effects, particularly nausea and digestive issues, are common and sometimes require dose reductions. Reassuringly, research from clinical trials has shown that patients on reduced doses maintain similar benefits to those on full doses. The choice between the two medications often comes down to side effect profiles and individual tolerance.
Beyond medication, supplemental oxygen becomes important as the disease progresses. Guidelines recommend long-term oxygen therapy when blood oxygen levels drop below certain thresholds at rest, or when lower oxygen levels are accompanied by signs of strain on the heart. For many people with IPF, oxygen therapy improves exercise capacity and day-to-day quality of life. Pulmonary rehabilitation, a structured program of exercise and breathing techniques, also helps maintain physical function.
When Lung Transplant Becomes an Option
IPF is the most common form of interstitial lung disease leading to lung transplant, and guidelines recommend referral to a transplant center early in the disease course rather than waiting until the lungs have severely deteriorated. Specific triggers for referral include lung function (specifically a measure called forced vital capacity) falling below 40% of what’s predicted for your age and size, any need for supplemental oxygen, or worsening breathlessness that limits daily activities.
Transplant centers generally consider candidates who face greater than a 50% chance of dying within two years without a transplant, along with a high likelihood of surviving the procedure and doing well afterward. Because IPF can decline unpredictably, with some patients experiencing sudden rapid worsening called acute exacerbations, earlier evaluation gives more time to complete the extensive workup and get on the waiting list. The number of IPF patients receiving transplants has increased dramatically over the past two decades as the transplant system has evolved to prioritize the sickest patients.
Living With IPF
The pace of IPF varies widely. Some people experience a slow, steady decline over many years, while others deteriorate rapidly over months. This unpredictability is one of the most difficult aspects of the disease. Acute exacerbations, sudden episodes of worsening that can happen without an obvious trigger, carry high mortality and can shift someone from stable to critically ill in days.
Staying physically active within your limits, avoiding respiratory infections (including getting vaccinated against flu and pneumonia), and quitting smoking if you haven’t already are practical steps that help preserve remaining lung function. Many people with IPF benefit from connecting with support groups, as the emotional toll of a progressive lung disease is substantial. Palliative care, which focuses on symptom relief and quality of life, is increasingly recognized as valuable alongside active treatment rather than reserved for end-stage disease.